Press release
AL Amyloidosis Pipeline Analysis 2024: FDA Approvals, Emerging Therapies, MOA, ROA by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Onco
"AL Amyloidosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AL Amyloidosis Market.
The AL Amyloidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the AL Amyloidosis Pipeline Report: https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel AL Amyloidosis treatment therapies with a considerable amount of success over the years.
• AL Amyloidosis companies working in the treatment market are HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others, are developing therapies for the AL Amyloidosis treatment
• Emerging AL Amyloidosis therapies in the different phases of clinical trials are- LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others are expected to have a significant impact on the AL Amyloidosis market in the coming years.
• In August 2024, Prothena Corporation plc (NASDAQ: PRTA) presented a highlighted poster for birtamimab at ISA 2024, showcasing additional efficacy analysis from the VITAL Phase 3 clinical trial for the treatment of AL amyloidosis. The company is also conducting the ongoing global confirmatory Phase 3 AFFIRM-AL clinical trial, with topline results anticipated between Q4 2024 and Q2 2025.
• In April 2024, Nexcella, a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company pioneering cell therapies for AL Amyloidosis and other autoimmune diseases, has announced that it is on schedule to begin dosing patients with NXC-201 in the U.S., with no changes to the planned patient enrollment timeline.
AL Amyloidosis Overview
AL amyloidosis, or primary amyloidosis, is a rare and serious condition characterized by the accumulation of abnormal proteins called amyloid fibrils in various organs and tissues. This buildup disrupts normal function and can lead to severe organ damage.
Get a Free Sample PDF Report to know more about AL Amyloidosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging AL Amyloidosis Drugs Under Different Phases of Clinical Development Include:
• LambdaMab: HaemaLogiX
• ZN d5: Zentalis Pharmaceuticals
• STI-6129: Sorrento Therapeutics
• Isatuximab: Sanofi
• Bendamustine: Astellas Pharma GmbH
• Belantamab mafodotin: GlaxoSmithKline
• Ixazomib: Takeda Oncology
• CAEL-101: Caelum Biosciences
AL Amyloidosis Route of Administration
AL Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
AL Amyloidosis Molecule Type
AL Amyloidosis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
AL Amyloidosis Pipeline Therapeutics Assessment
• AL Amyloidosis Assessment by Product Type
• AL Amyloidosis By Stage and Product Type
• AL Amyloidosis Assessment by Route of Administration
• AL Amyloidosis By Stage and Route of Administration
• AL Amyloidosis Assessment by Molecule Type
• AL Amyloidosis by Stage and Molecule Type
DelveInsight's AL Amyloidosis Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further AL Amyloidosis product details are provided in the report. Download the AL Amyloidosis pipeline report to learn more about the emerging AL Amyloidosis therapies at:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the AL Amyloidosis Therapeutics Market include:
Key companies developing therapies for AL Amyloidosis are - Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and others.
AL Amyloidosis Pipeline Analysis:
The AL Amyloidosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of AL Amyloidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AL Amyloidosis Treatment.
• AL Amyloidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• AL Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AL Amyloidosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about AL Amyloidosis drugs and therapies:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
AL Amyloidosis Pipeline Market Drivers
• Increase in the number of patients suffering from AL Amyloidosis, increase in awareness about the disease are some of the important factors that are fueling the AL Amyloidosis Market.
AL Amyloidosis Pipeline Market Barriers
• However, high cost of the associated treatment, side effects associated with the treatment and other factors are creating obstacles in the AL Amyloidosis Market growth.
Scope of AL Amyloidosis Pipeline Drug Insight
• Coverage: Global
• Key AL Amyloidosis Companies: HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others
• Key AL Amyloidosis Therapies: LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others
• AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed and AL Amyloidosis emerging therapies
• AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers
Request for Sample PDF Report for AL Amyloidosis Pipeline Assessment and clinical trials:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. AL Amyloidosis Report Introduction
2. AL Amyloidosis Executive Summary
3. AL Amyloidosis Overview
4. AL Amyloidosis- Analytical Perspective In-depth Commercial Assessment
5. AL Amyloidosis Pipeline Therapeutics
6. AL Amyloidosis Late Stage Products (Phase II/III)
7. AL Amyloidosis Mid Stage Products (Phase II)
8. AL Amyloidosis Early Stage Products (Phase I)
9. AL Amyloidosis Preclinical Stage Products
10. AL Amyloidosis Therapeutics Assessment
11. AL Amyloidosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. AL Amyloidosis Key Companies
14. AL Amyloidosis Key Products
15. AL Amyloidosis Unmet Needs
16 . AL Amyloidosis Market Drivers and Barriers
17. AL Amyloidosis Future Perspectives and Conclusion
18. AL Amyloidosis Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports:
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AL Amyloidosis Pipeline Analysis 2024: FDA Approvals, Emerging Therapies, MOA, ROA by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Onco here
News-ID: 3816737 • Views: …
More Releases from DelveInsight Business Research
IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, PDMA, FDA Approval …
(Albany, USA) DelveInsight's 'IgA Nephropathy Pipeline Insight 2025' report provides comprehensive global coverage of available, marketed, and pipeline IgA nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the IgA nephropathy pipeline domain.
IgA nephropathy pipeline report showcase a robust space with 30+ key companies working to develop 30+ pipeline therapies for IgA nephropathy treatment.
IgA nephropathy companies…
Candidemia Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, Medi …
(Albany, United States) "Candidemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Candidemia Market.
As per DelveInsight's assessment, globally, Candidemia pipeline constitutes 4+ key companies continuously working towards developing 4+ Candidemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Request for Sample Report here @ https://www.delveinsight.com/report-store/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways…
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Clinical Trials and Pipeline Analy …
(Albany, United States) "CAR T-Cell Therapy for Non-Hodgkin's lymphoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market.
As per DelveInsight's assessment, globally, CAR T-Cell Therapy for Non-Hodgkin's lymphoma pipeline constitutes 5+ key companies continuously working towards developing 5+ CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism…
Cystinosis Clinical Trials and Pipeline Assessment: EMA, PDMA, FDA Approvals, Me …
(Albany, USA) DelveInsight's 'Cystinosis Pipeline Insight 2025' report provides comprehensive global coverage of available, marketed, and pipeline Cystinosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystinosis pipeline domain.
Request for Cystinosis sample pages @ https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Cystinosis Pipeline Report
• Over 5+ Cystinosis pipeline therapies are in various stages of development, and their anticipated…
More Releases for Amyloidosis
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
Amyloidosis Treatment Market Size - Forecasts to 2026
As per the research conducted by GME, the Amyloidosis Treatment Market will grow with a CAGR value of 6.8 percent. The global amyloidosis treatment market is foreseen to rise rapidly throughout the forecast period because of the increasing likelihood of amyloidosis targeted therapies releases, a growing core patient demographic since they are biologically prone to amyloidosis, surging healthcare understanding amongst individuals, and increasing disposable incomes of consumers.
Browse 151 Market Data…
New Visiongain Report: Amyloidosis Treatment Market Report 2019-2029
Amyloidosis Treatment Market Report 2019-2029
By Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), by Country and Segment Forecasts
Purchase full report or download free sample pages: https://www.visiongain.com/report/amyloidosis-treatment-market-report-2019-2029/
Amyloidosis is a group of rare diseases in which misfolded aggregates of protein (amyloid) accumulate in tissues and organs. The currently available amyloidosis treatments provide symptomatic relief and palliative care. These include chemotherapy, targeted therapy, supportive therapy, surgery and stem cell transplantation. High-dose…
Transthyretin Amyloidosis Treatment Market - Global Industry Analysis 2025
Transthyretin amyloidosis is a rare disease caused due to abnormal build-up of amyloidosis in the tissues of the body. The deposits of transthyretin amyloids cause illness due to damage in structure and function of the organs and moreover, they can affect any part of the body where deposits of transthyretin amyloids are present. The deposits mainly consists of abnormal, insoluble protein fibers called amyloid fibrils that are soluble in healthy…
Global Amyloidosis Therapeutics Pharmaceuticals Industry Research Report - MRH
To study the market for Amyloidosis in a precise manner, Market Research Hub (MRH) has included a new research report. The report is titled “Global Amyloidosis Therapeutics Market Research Report”, which enlightens the readers about the market share as well as growth rate during the period 2017-2022. The research study estimates that the Pharmaceutical sector would be rising with a positive CAGR during the same stated forecast period.
Request For Free…
Transthyretin Amyloidosis Treatment Market - Global Industry Insights – 2025
Transthyretin amyloidosis is a rare disease caused due to abnormal build-up of amyloidosis in the tissues of the body. The deposits of transthyretin amyloids cause illness due to damage in structure and function of the organs and moreover, they can affect any part of the body where deposits of transthyretin amyloids are present. The deposits mainly consists of abnormal, insoluble protein fibers called amyloid fibrils that are soluble in healthy…
